Tumor-specific T-cell help is associated with improved survival in melanoma

Katherine Woods; Jonathan Cebon

doi:10.1158/1078-0432.CCR-13-1349

Tumor-specific T-cell help is associated with improved survival in melanoma

Clin Cancer Res. 2013 Aug 1;19(15):4021-3. doi: 10.1158/1078-0432.CCR-13-1349. Epub 2013 Jul 17.

Authors

Katherine Woods¹, Jonathan Cebon

Affiliation

¹ Ludwig Institute for Cancer Research Melbourne-Austin Branch, Heidelberg, Australia.

PMID: 23864163
DOI: 10.1158/1078-0432.CCR-13-1349

Abstract

Despite success with immune checkpoint inhibitors, clinical benefit from cancer vaccines remains elusive. Combined targeting of melanoma-specific CD4(+) and CD8(+) T-lymphocyte epitopes was associated with improved survival compared with targeting either alone, or when a nonspecific helper epitope was used. We discuss the potential role of antigen-specific CD4 help.

MeSH terms

CD4 Antigens / immunology
CD4-Positive T-Lymphocytes*
CD8-Positive T-Lymphocytes*
Cancer Vaccines / immunology*
Cancer Vaccines / therapeutic use
Epitopes, T-Lymphocyte / immunology
Flow Cytometry
Humans
Immunotherapy
Lymphocyte Activation / immunology
Melanoma / immunology
Melanoma / pathology
Melanoma / therapy*
Survival Analysis

Substances

CD4 Antigens
Cancer Vaccines
Epitopes, T-Lymphocyte